Technical Analysis for AGLE - Aeglea BioTherapeutics, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| See historical AGLE trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| 1,2,3 Retracement Bearish | Bearish Swing Setup | -5.68% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -5.68% | |
| Up 3 Days in a Row | Strength | -5.68% | |
| Earnings Movers | Other | -5.12% | |
| MACD Bullish Signal Line Cross | Bullish | -4.85% | |
| Lower Bollinger Band Walk | Weakness | -4.85% | |
| Earnings Movers | Other | -4.85% | |
| Outside Day | Range Expansion | -4.85% | |
| Lower Bollinger Band Touch | Weakness | -4.85% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/14/2019
- Sector: Healthcare
- Industry: Biotechnology
Aeglea Biotherapeutics, Inc., a biopharmaceutical company, engages in developing engineered human enzymes for the treatment of inborn errors of metabolism and cancer. It develops AERase/AEB1102, an amino acid for the degradation of arginine in the circulation, as well as for the treatment of hyperargininemia and cancer; and AECase/AEB3103, an engineered and PEGylated human cysteine/cystine degrading enzyme that increases oxidative stress through glutathione depletion for treatment of hematologic and solid malignancies. The company also engages in developing AEMase/AEB2109, an engineered human enzyme that degrades methionine for the treatment of solid tumors; and AEB4104, an engineered human enzyme that degrades homocysteine in the circulation for the treatment of inborn error of metabolism homocystinuria. It has a strategic partnership with KBI Biopharma. Aeglea Biotherapeutics, Inc. was formerly known as Aeglea BioTherapeutics Holdings, LLC. The company was founded in 2013 and is based in Austin, Texas.
Chemistry Biopharmaceutical Cancer Solid Tumors Organic Chemistry Inborn Errors Of Metabolism
Chemistry Biopharmaceutical Cancer Solid Tumors Organic Chemistry Inborn Errors Of Metabolism
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more AGLE news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 12.0 |
| 52 Week Low | 6.31 |
| Average Volume | 173,879 |
| 200-Day Moving Average | 8.4097 |
| 50-Day Moving Average | 7.5526 |
| 20-Day Moving Average | 6.9365 |
| 10-Day Moving Average | 6.785 |
| Average True Range | 0.3431 |
| ADX | 38.88 |
| +DI | 12.3904 |
| -DI | 27.271 |
| Chandelier Exit (Long, 3 ATRs ) | 6.5307 |
| Chandelier Exit (Short, 3 ATRs ) | 7.4493 |
| Upper Bollinger Band | 7.4666 |
| Lower Bollinger Band | 6.4064 |
| Percent B (%b) | 0.07 |
| BandWidth | 15.284365 |
| MACD Line | -0.2506 |
| MACD Signal Line | -0.2628 |
| MACD Histogram | 0.0122 |
| Fundamentals | Value |
|---|---|
| Market Cap | 106.61 Million |
| Num Shares | 16.5 Million |
| EPS | -1.81 |
| Price-to-Earnings (P/E) Ratio | -3.58 |
| Price-to-Sales | 15.71 |
| Price-to-Book | 1.22 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.16 | ||||
| Resistance 3 (R3) | 7.22 | 7.05 | 7.05 | ||
| Resistance 2 (R2) | 7.05 | 6.87 | 7.02 | 7.01 | |
| Resistance 1 (R1) | 6.76 | 6.77 | 6.68 | 6.71 | 6.97 |
| Pivot Point | 6.59 | 6.59 | 6.55 | 6.56 | 6.59 |
| Support 1 (S1) | 6.31 | 6.42 | 6.22 | 6.25 | 5.99 |
| Support 2 (S2) | 6.14 | 6.31 | 6.11 | 5.95 | |
| Support 3 (S3) | 5.85 | 6.14 | 5.91 | ||
| Support 4 (S4) | 5.80 |
